Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Neuroimmune Pharmacol. 2015 Nov 4;11(1):9–25. doi: 10.1007/s11481-015-9637-6

Fig. 3. H150 immunostaining following antibody treatment to rTg4510 mice.

Fig. 3

One year old rTg4510 mice (n = 6 – 7 per group) received intracranial injections of treatment antibodies into the right hippocampus. Four days later, tissue was collected and the treated (right) hippocampus was compared to the untreated (left) hippocampus to identify differences in pathology by IHC. Results were compared between antibody treatments and anti-GFP control injections. Both MC-1 and DA 9 treatments led to significant reductions in H150 pathology (p < 0.05) compared to the anti-GFP control treatments. Results were analyzed using StatView software, for the non-parametric Mann Whitney U Test. Scale bar = 100 μm